Showing 1 - 20 results of 70,300 for search '(((( 5 g decrease ) OR ( 50 mg decrease ))) OR ( 50 ((we decrease) OR (_ decrease)) ))*', query time: 0.99s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  7. 7

    Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

    Published 2024
    “…(A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    Trial profile. by Chanel Avenant (409756)

    Published 2024
    Subjects:
  13. 13
  14. 14
  15. 15
  16. 16

    Nasal mucociliary clearance was decreased in <i>Ttll1</i><sup>−/−</sup> mice. by Toshiyuki Iwata (419270)

    Published 2015
    “…<p>(A) Tosufloxacin (50 mg/kg) was administered to <i>Ttll1</i><sup>−/−</sup> mice with rhinosinusitis to inhibit cough for 7 days. …”
  17. 17

    Proportion of participants with sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment value and to < 8100 mf/ml. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Proportion of participants with sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment value and to < 8100 mf/ml.…”
  18. 18
  19. 19
  20. 20